» Articles » PMID: 38184624

Association Between Maternal Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology and Pregnancy Complications and Neonatal Outcomes: a Systematic Review and Meta-analysis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Polycystic ovarian syndrome (PCOS) is recognized as the most prevalent endocrine disorder among women of reproductive age. While the utilization of assisted reproductive technology (ART) has resulted in favorable outcomes for infertility treatment in PCOS patients, the inherent pathophysiological features of the condition give rise to complications and consequences during pregnancy and delivery for both the mother and offspring. This study was to assess the correlation between maternal PCOS and various pregnancy complications and neonatal outcomes undergone ART.

Methods: A systematic search was conducted on PubMed, EmBase, and the Cochrane Library to identify observational studies that investigated the association between PCOS and the risk of various pregnancy complications and neonatal outcomes, including gestational diabetes mellitus (GDM), hypertension in pregnancy (PIH), preeclampsia (PE), preterm birth, abortion, congenital malformations (CA), small for gestational age (SGA), large for gestational age (LGA), low birth weight (LBW), macrosomia, neonatal intensive care unit (NICU) admission and birth weight. Eligible studies were selected based on predetermined inclusion and exclusion criteria. The meta-analysis was conducted using Review Manager and Stata software, with odds ratios (ORs) or mean difference (MD), confidence intervals (CIs), and heterogeneity (I) being calculated. The search was conducted up to March 2023.

Results: A total of 33 studies with a combined sample size of 92,810 participants were identified. The findings indicate that PCOS is significantly associated with an increased risk of GDM (OR 1.51, 95% CI:1.17-1.94), PIH (OR 1.72, 95% CI:1.25-2.39), PE (OR 2.12, 95% CI:1.49-3.02), preterm birth (OR 1.29, 95% CI:1.21-1.39), and LBW (OR 1.29, 95% CI:1.14-1.47). In subgroup analyses, the risks of GDM (OR 1.80, 95% CI:1.23-2.62) and abortion (OR 1.41, 95% CI:1.08-1.84) were elevated in fresh embryo transferred (ET) subgroup, whereas elevated risk of PE (OR 1.82, 95% CI:1.17-2.83) and preterm birth (OR 1.31, 95% CI:1.21-1.42) was identified in frozen ET subgroup. Whatever with or without hyperandrogenism, patients with PCOS had a higher risk in preterm birth (OR 1.69, 95% CI: 1.31-2.18; OR 1.24, 95% CI:1.02-1.50) and abortion (OR 1.38, 95% CI:1.12-1.71; OR 1.23, 95% CI:1.06-1.43).

Conclusion: Our findings suggest that individuals with PCOS undergone ART are at a notably elevated risk for experiencing pregnancy complications and unfavorable neonatal outcomes. Nevertheless, to establish a definitive association between PCOS and pregnancy-related outcomes, it is necessary to conduct extensive prospective, blinded cohort studies and effectively control for confounding variables.

Citing Articles

Enhancing understanding of endometrial function in patients with PCOS: clinical and immunological insights.

Guo Y, Yang J, Chen H, Zhou Y, Yang Y, Wang B J Ovarian Res. 2025; 18(1):52.

PMID: 40075432 PMC: 11900192. DOI: 10.1186/s13048-025-01638-x.


Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS.

Quaresima P, Myers S, Pintaudi B, DAnna R, Morelli M, Unfer V Front Endocrinol (Lausanne). 2025; 16:1501110.

PMID: 39959624 PMC: 11825335. DOI: 10.3389/fendo.2025.1501110.


Causal relationships exist between polycystic ovary syndrome and adverse pregnancy and perinatal outcomes: a Mendelian randomization study.

Ma Y, Cai J, Liu L, Wen T, Huang W, Hou W Front Endocrinol (Lausanne). 2024; 15:1327849.

PMID: 39006363 PMC: 11239544. DOI: 10.3389/fendo.2024.1327849.


ChatGPT's Efficacy in Queries Regarding Polycystic Ovary Syndrome and Treatment Strategies for Women Experiencing Infertility.

Devranoglu B, Gurbuz T, Gokmen O Diagnostics (Basel). 2024; 14(11).

PMID: 38893609 PMC: 11172366. DOI: 10.3390/diagnostics14111082.

References
1.
Sha T, Wang X, Cheng W, Yan Y . A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019; 39(2):281-293. DOI: 10.1016/j.rbmo.2019.03.203. View

2.
Shahrokh Tehrani Nejad E, Saedi T, Saedi S, Hossein Rashidi B, Nekoo Z, Jahangiri N . Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. Gynecol Endocrinol. 2010; 27(2):117-20. DOI: 10.3109/09513590.2010.501872. View

3.
. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

4.
Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben-Rafael Z . In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril. 1993; 60(5):858-63. DOI: 10.1016/s0015-0282(16)56287-6. View

5.
Ryan E . Hormones and insulin resistance during pregnancy. Lancet. 2003; 362(9398):1777-8. DOI: 10.1016/S0140-6736(03)14942-2. View